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LATORY T CELLS (T reg), MODULATES GVHD, AND INCREASES SURVIVAL
AFTER ALLOGENEIC TRANSPLANTATION
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Graft-versus-host disease (GVHD) is an important complication
of allogeneic hematopoietic cell transplantation (HCT).We showed
in a minor antigen mismatched murine transplant model that treat-
ment with human (serum derived) alpha-1-anti-trypsin (AAT) pre-
vented or attenuated acute GVHD and resulted in significantly
improved survival (p\0.04). AAT reduced production of pro-inflam-
matory cytokines and induced anti-inflammatory cytokines. In this
model pro-inflammatory cytokines such as IL-1B and IL-32 were re-
duced while anti-inflammatory cytokines such as IL-1RA were in-
creased. This shift in cytokine levels suggested a possible impact
on the function of antigen presenting cells, includingDendritic Cells
(DCs) and T cell activation. DCs are specialized to capture and pro-
cess antigens for presentation on MHC products and modify subse-
quent differentiation of T cells. We hypothesized that alteration of
cytokine levels would modify the spectrum of T cells. In a dog model
of unrelated DLA non-identical HCT we showed that AAT given
every other day for 3 doses (60 mg/kg/day), resulted in improvement
of clinical manifestations of active acute GVHD and concurrently
reduced the expression of TNFa and IL-1b mRNA, while IL-1Ra
was increased. Strikingly, the proportion of CD4+CD25hi FoxP3+
Treg cells significantly increased in parallel with a decline in pro-in-
flammatory cytokines. Therefore, we extended our studies in AAT
treated mice and used multi-parameter flow cytometry to detect
changes in spleen and bone marrow cells, focusing on CD4+CD25hi
FoxP3+Treg cells andCD8+/CD205+DCs and expression ofMHC
class II in comparison to albumin treated controls. CD8+/CD205+
MHC class II DCs in the spleen increased 20 fold and CD4+CD25hi
FoxP3+ Treg cells 10 fold in AAT treated mice. Extensive literature
supports that CD8+/CD205+ DCs in the intestine and the spleen is
specialized to induce cell tolerance.
Conclusion:We propose that AAT delivered prophylactically in this
transplant model resulted in induction of CD4+CD25hi FoxP3+ Treg
cells, presumably facilitated via DCs maturation and expansion,
thereby contributing to the development of tolerance. In light of its
long safety record in humans, these findings suggest that AAT should
be tested as a novel strategy to mitigate clinical GVHD.
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Background:The role of matching forMICA andHLA-DP (DP) in
AHPCT remains unclear. We investigate the impact of these mis-
matches (MM) on post-transplant outcomes.
Methods:We studied 269 patients (100 AML, 44 ALL, 42MDS, 31
NHL, 17 CML, and 35 others) who had AHPCT at our institute be-
tween 2000-2010. BM and PSC were the sources of HPC in 168 and
101 patients. Myeloablative and reduced intensity conditioning were
used in 202 and 67 patients. GVHD prophylaxis consisted of a calci-
neurin inhibitor andmycophenolate ormethotrexate.MICA andDP
genotyping was performed by rSSOP (One Lambda, Inc, CA). Cox
proportional hazards analysis was used to identify univariable and
multivariable prognostic factors for outcomes. Exploratory recursive
partitioning analysis (RPA) with log-rank splitting was used to eval-uate the combined effect of MICA and DP MM on outcomes. Out-
comes from groups identified by RPA were estimated using the
Kaplan-Meier method and compared using the log-rank test.
Results: The number of patients with 8/8 (A/B/C/DRB1), 7/8, and
6/8 matches were 219, 48, and 2 respectively. One and 2 MICAMM
were observed in 27 and 2 patients among 228 with samples available
for testing. One and 2DPMMwere observed in 139 and 80 patients.
Patients with 1-2MICAMMhad a significantly greater risk of severe
aGvHD (Grade III-IV) than those with no MICA MM (HR 3.05,
95% CI 1.52-6.12, P 5 0.002); 100-day incidence was 39% vs.
15%. Patients with 1-2 DPMM had a greater risk of severe aGvHD
than those with no DP MM (HR 3.15, 95% CI 0.97-10.20, P 5
0.06); 100-day incidence was 20% and 8%. These results remained
consistent in multivariable analysis (HRadj 2.78, 95% CI 1.38-5.59,
P 5 0.004 for MICA MM; HRadj 2.78, 95% CI 0.85-9.08, P 5
0.09 for DP MM). RPA identified 3 groups based on MICA and
DP MM, from highest to lowest risk: 1-2 MICA MM and 1-2 DP
MM, noMICA and 1-2DPMM, and noDPMM. 100-day incidence
of severe aGvHD among these three groups was 38%, 17%, and 8%
(P 5 0.002; log-rank test). Mismatches at MICA and DP were not
associated with time to neutrophil or platelet engraftment, cGvHD,
relapse, relapse mortality, non-relapse mortality, or survival.
Conclusion: MICA MM are associated with significantly increased
risk of severe aGVHD. Among patients with DP MM, MICA MM
further increases the risk of severe acute GvHD. Further investiga-
tion of these observations in larger cohorts is warranted.56
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NK cells play an important role in immunity against viruses and
malignancy. Alleles for KIR3DL1/S1 are associated with improved
outcome in HIV infection. Previous studies have shown differential
impact of associations between 3DL1 alleles (3DL1-high, -low,
-null) and Bw4 alleles (I80, T 80), where higher affinity combinations
appear to secure stronger NK response in viral control.
Because NK cells play an important role in HSCT we hypothe-
sized that 3DL1 alleles and their hierarchically binding Bw4 ligands
would have differential outcomes in HSCT. We performed donor
3DL1/S1 allele typing for 426 patients with myeloid malignancies
(AML 70.2%, CML 6.3%, MDS 23.5%) who received URD
HSCT. 349 patients received 10/10 HLA matched HSCT, 77 re-
ceived 9/10 or 8/10 HLA-matched. All patients received an ablative
conditioning regimen and 364 patients received T-replete allografts.
Overall Bw4-I80 donors were associated with higher relapse com-
pared to Bw6 homozygous and Bw4-T80 donors (HR 1.48; P 5
.05). Not surprisingly, this association was stronger in Bw4-I80 and
3DL1-positive donors (HR1.59; P5 .03).While therewere no overall
differences in outcomes among recipients of donors with 3DL1-null
(27.96%), 3DL1-high (41.70%) or 3DL1-low (25.83%) allotypes,
the combination of 3DL1-high and Bw4-I80 donors, compared with
3DL1-high and Bw6 homozygous or Bw4-T80 donors, were strongly
associatedwith relapse (HR 2.71; P5 .001).When the analysis was re-
stricted to AML patients alone (n 5 299), 3DL1-high and Bw4-I80
donors remained associated with higher relapse (HR 2.10; P 5 .04).
There was no association between 3DL1-high/Bw4 compound
genotypes and NRM or aGVHD, nor between 3DL1-null and
3DL1-low and Bw4 with any outcome. In contrast, we confirmed
in this cohort our previous findings that 3DS1-positive donors
